
[4mUSAGE[0m
 [1mgenome model define clin-seq[0m --processing-profile=? [--add-to-projects=?[,?]] [--name=?]
    [--wgs-model=?] [--exome-model=?] [--tumor-rnaseq-model=?] [--normal-rnaseq-model=?]
    [--de-model=?] [--cancer-annotation-db=?] [--misc-annotation-db=?] [--cosmic-annotation-db=?]
    [--force]

[4mSYNOPSIS[0m

    genome processing-profile create clin-seq  --name 'November 2011 Clinical Sequencing' 

    genome model define clin-seq  --processing-profile='November 2011 Clinical Sequencing'  --wgs-model=2882504846 --exome-model=2882505032 --tumor-rnaseq-model=2880794613
    
    # Automatically builds if/when the models have a complete underlying build

[4mREQUIRED INPUTS[0m
  [1mprocessing-profile[0m
    the collection of parameters to be used during the build process 

[4mOPTIONAL INPUTS[0m
  [1madd-to-projects[0m
    add the new model to these projects (model groups) 
  [1mname[0m
    a friendly name for the new model (changeable) 
  [1mwgs-model[0m
    somatic variation model for wgs data 
  [1mexome-model[0m
    somatic variation model for exome data 
  [1mtumor-rnaseq-model[0m
    rnaseq model for tumor rna-seq data 
  [1mnormal-rnaseq-model[0m
    rnaseq model for normal rna-seq data 
  [1mde-model[0m
    differential-expression for tumor vs normal rna-seq data 
  [1mcancer-annotation-db[0m
    (undocumented) 
    Default value 'tgi/cancer-annotation/human/build37-20130401.1' if not specified
  [1mmisc-annotation-db[0m
    (undocumented) 
    Default value 'tgi/misc-annotation/human/build37-20130113.1' if not specified
  [1mcosmic-annotation-db[0m
    (undocumented) 
    Default value 'cosmic/65.1' if not specified
  [1mforce[0m
    skip sanity checks on input models 
  [1mnoforce[0m
    Make force 'false' 

[4mDESCRIPTION[0m
    The ClinSeq pipeline takes four models, each of which is optional, and produces data sets
    potentially useful in a clinical or discovery project.

    There are several primary goals:

    1. Generate results that help to identify clinically actionable events (gain of function
    mutations, amplifications, etc.)

    2. Converge results across data types for a single case (e.g. variant read counts from wgs +
    exome + rnaseq)

    3. Automatically generate statistics, tables and figures to be used in manuscripts

    4. Test novel analysis methods in a pipeline that runs faster and is more agile than say
    somatic-variation



